本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG SAR - Media OurReach Newswire - 13 November 2025 - Citi hosted its 2025 China Conference this week and released an updated research report on Fosun International (00656.HK), reiterating its "Buy" rating and raising the target price to HK$6.5. Citi remains positive on Fosun's business streamlining and core business-focused strategy. Following a series of recent meetings with Fosun's management team, Citi noted that the discussions reflected a clear strategic direction. Management has indicated that Fosun will continue to focus on its core businesses, deepen its global presence, and continue to step up innovation efforts. Citi also notes Fosun's ongoing efforts to optimize its financial structure and highlights its firm commitment to deleveraging and divesting non-core assets. Fosun's business streamlining approach will not only enhance financial resilience but also sharpen the Group's strategic focus on core businesses to unlock long-term value. UBS, in its latest research report, also notes Fosun's proactive steps to dispose non-core assets, optimize its asset portfolio, and increase cash flow amid improving equity market sentiment and valuation, thus raising the target price for Fosun International. In fact, multiple domestic and international securities firms, including Citi, Industrial Securities, Kaiyuan Securities, Huaxi Securities, SDIC Securities, China Securities, and Founder Securities, currently hold "Buy" or "Overweight" ratings on Fosun International, with target prices ranging from HK$6.5 to HK$7.5. They are confident in Fosun's solid business resilience and innovation-driven growth. Citi highlights that Fosun's health and insurance businesses will provide long-term profit momentum for the Group, while securities firms such as Industrial Securities and Huaxi Securities remain upbeat on the sustained breakthroughs in Fosun's core cultural tourism and consumer businesses. Powered by continuous innovation, Fosun's Health segment has achieved multiple breakthroughs in the field of innovative drugs, earning strong endorsements from securities firms. Among which, HANSIZHUANG, an anti-PD-1 monoclonal antibody independently developed by Fosun, has become the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore, and India. Additionally, HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) independently developed by Fosun, is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential highly effective and safe broad-spectrum anticancer drug. In the insurance business, Fidelidade maintained steady growth in 2024. It recorded a 12.7% year-on-year increase in insurance income, with net profit for the full year reaching EUR253 million. In July 2025, S&P assigned Fidelidade an "A" rating. It anticipates that, over the next two years, Fidelidade will continue to maintain its leading positions in both Portugal and international markets, and sustain robust capital strength and profitability to achieve steady growth. In the cultural tourism business, during the National Day and Mid-Autumn Festival holidays in 2025, Taicang Alps International Resort welcomed over 50,000 visitors, while Lijiang Club Med Resort reported full occupancy for three consecutive days. In addition, the six resorts of Club Med Urban Oasis and Club Med Joyview saw their average daily room rates increase nearly 10% year-on-year. In particular, the Heilongtan resort sustained an occupancy rate above 94% for six consecutive days, driving a 36% year-on-year increase in total business volume for Club Med in China and a 213% surge in inbound tourists. Meanwhile, Atlantis Sanya achieved a 20% year-on-year increase in average daily room rate, further consolidating its leadership in the high-end resort market. In the consumer business, securities firms note that Yuyuan is accelerating adjustments to its overall operating strategy. While short-term earnings are experiencing pressure, the jewelry segment's results indicate the company has entered the latter stage of its adjustment cycle, with core businesses gradually recovering. Citi also highlights the positive sequential momentum in Yuyuan's gold and jewelry business, demonstrating the resilience of Fosun's consumer portfolio. The market broadly anticipates that with a moderate recovery in the consumer market, the establishment of the Shanghai International Jewelry & Style District, and the deepening of global presence, Yuyuan is poised to establish new growth drivers in core areas such as jewelry fashion and commercial operations, unlocking greater growth potential. Fosun continues to promote innovation in asset management and fintech, gaining recognition from domestic and international securities firms including Citi. In the research report, Citi highlights Fosun's increased resources and attention to fintech and Web3.0 businesses and notes that its subsidiary Finloop Finance Technology has emerged as a leading fintech company in the Hong Kong market. Incubated by Fosun Wealth, Finloop Finance Technology is positioned as an AI-driven, one-stop Web5 (Web2 + Web3) wealth technology platform with licensed operations in Hong Kong. Huaxi Securities and SDIC Securities highlight that Finloop Finance Technology is making steady progress in the virtual asset market with the launch of its FinRWA platform. Powered by a proprietary research and development system, the FinRWA platform provides enterprises and financial institutions with compliant and efficient access to Web3, supporting tokenized issuance and distribution of both public and private funds. It has already executed several innovative projects, including the launch of the Hong Kong's first platform for multi-currency tokenized funds, facilitating the rollout of Hong Kong's first tokenized fund under a unit trust structure, and the debut of Asia's first comprehensive technical solution for "Hong Kong Stock Performance-Linked Token". In April this year, Finloop Finance Technology was recognized by the Office for Attracting Strategic Enterprises (OASES) of the Government of the Hong Kong Special Administrative Region as one of its key enterprises. Multiple securities firms note that Fosun's core businesses are operating steadily. With a continued focus on industries of strength and potential, Fosun is deepening its global presence and intensifying its technology innovation efforts, thereby shaping a resilient business framework capable of withstanding economic cycles. Consequently, these firms maintain an optimistic outlook on Fosun International's long-term growth. Hashtag: #FosunThe issuer is solely responsible for the content of this announcement.
Company builds on first half performance to reach record nine-month revenue of US$9.53 billion, up 21% year-on-year Higher plantation output helped the Company capitalise on CPO price increase EBITDA for the first nine months of 2025 rose by 16% to US$882 million, with recovery in downstream merchandising volume complementing upstream performance. SINGAPORE, Nov. 13, 2025 /PRNewswire/ -- Golden Agri-Resources Ltd ("GAR" or the "Company") continued its run of record-high revenue for a second consecutive quarter, recording US$9.53 billion for the nine-month period of 2025. Higher plantation output helped the Company capitalise on a 17% rise in crude palm oil ("CPO") prices (FOB Belawan), while a modest increase in downstream volume further supported revenue growth. GAR recorded record-high revenue for the first nine months of 2025; continuing its first-half record revenue trend. Nine-month EBITDA grew by 16% to reach US$882 million, preserving a healthy margin of 9.3%. Foreign exchange loss increased from US$2 million in the same period last year to US$15 million. Net profit remained strong, growing by 29% to reach US$284 million. GAR's balance sheet has also been strengthened, with an improved gearing ratio of 0.56 times and a much lower net debt to EBITDA ratio of 0.10 times. On the outlook, Mr. Franky O. Widjaja, GAR Chairman and Chief Executive Officer commented: "Vegetable oil industry fundamentals remain robust, driven by steady and rising global demand. Limitations in supply growth capability, often compounded by unfavourable weather conditions, present ongoing challenges to meeting this demand. For palm oil, short- and medium-term supply growth has been constrained by ageing plantations and replanting activity which provide support to CPO prices. The market is also paying close attention to any changes in biofuel blending mandates across the world. Any shifts in trade, energy, and sustainability policies, coupled with geopolitical tensions, will have significant ripple effects on market dynamics, causing price volatility." Operational Highlights Upstream output grew by 6% year-on-year, with modest increase in downstream volume despite volatile global economic environment GAR has continued replanting its old estates as part of the Company's long-term yield improvement initiative. As a result, GAR's planted area as of 30 September 2025 declined slightly to around 531,000 hectares, of which 491,000 hectares were mature. Nucleus and plasma estates made up 414,000 and 117,000 hectares of this area, respectively. Fruit yield for the nine months of 2025 rose by 6% year on year from 12.8 to 13.6 tonnes per hectare supported by favourable weather conditions. This translated into a total fruit output of 6.7 million tonnes, with a corresponding increase in palm product output of 6% to almost 2.0 million tonnes. The Company's downstream business continued to make progress amidst a volatile global economic environment. While competitive market conditions have constrained downstream performance, GAR's merchandising volumes have continued to rise over the last two quarters, resulting in increased sales volume for the nine-month period. The Company will continue to strengthen its competitive edge through value-added products tailored to customer demands for functionality, quality and sustainability; anticipating factors that may influence price trends and trade flows while continuing to deliver on its commitments to responsible production. Investment in Sustainability GAR continues to advance its sustainability ambitions under the Company's Collective for Impact commitments. GAR has commissioned three new methane capture plants at its mills in 2025, targeting annual CO₂e reductions of 150,000 tonnes from its Scope 1 emissions. The Company has surpassed 2025 targets for its flagship independent smallholder programme Sawit Terampil, reaching 11,000 farmers by the end of September 2025. The programme helps smallholders to improve productivity, meet regulatory requirements, and access sustainable markets through recognised sustainability certification schemes. Almost 300 participants were awarded Roundtable on Sustainable Palm Oil certification at the organisation's recent Roundtable Conference, bringing the total number of smallholders certified to 800. At the recent Asia Sustainability Reporting Awards, GAR's commitment to transparency and quality reporting was recognised with the Platinum Award for Supply Chain Reporting and the Bronze Award for Environmental Impact Reporting. These recognitions reaffirm GAR's dedication to transparent and credible sustainability disclosures aligned with leading reporting standards. About Golden Agri-Resources Ltd (GAR) GAR is a leading fully-integrated agribusiness company. In Indonesia, it manages an oil palm plantation area of approximately 531,000 hectares (including plasma smallholders) as of 30 September 2025. It has integrated operations focused on the technology-driven production and distribution of an extensive portfolio of palm-based products throughout its established international marketing network. Founded in 1996, GAR was listed on the Singapore Exchange in 1999 and has a market capitalisation of US$2.9 billion as of 30 September 2025. Flambo International Limited, an investment company, is GAR's largest shareholder, with a 50.56% stake. In addition, GAR's subsidiary, PT SMART Tbk was listed on the Indonesia Stock Exchange in 1992. As an integrated agribusiness, GAR delivers an efficient end-to-end supply chain, from responsible production to global delivery. In Indonesia, its primary activities include cultivating and harvesting oil palm trees; the processing of fresh fruit bunch into crude palm oil (CPO) and palm kernel; refining CPO into value-added products such as cooking oil, margarine, shortening, biodiesel and oleo-chemicals; as well as merchandising palm products globally. GAR's products are delivered to a diversified customer base in over 110 countries through its global distribution network with shipping and logistics capabilities, destination marketing, on-shore refining and ex-tank operations. GAR also has complementary businesses such as soybean-based products in China, sunflower-based products in India, and sugar businesses.
Highlights of FY25/26 Half-Year Results Group sales US$1,833 million – down 1% compared to first half of the prior financial year Gross profit US$441 million or 24.0% of sales (compared to US$438 million or 23.6% of sales in the first half of the prior financial year) Adjusted EBITA US$159 million or 8.7% of sales (compared to US$177 million or 9.5% of sales in the first half of the prior financial year) Net profit attributable to shareholders increased by 3% to US$133 million or 14.21 US cents per share on a fully diluted basis Underlying net profit, excluding the net impact of unrealized gains or losses relating to exchange rate movements and restructuring costs, decreased by 8% to US$123 million Free cash flow from operations US$174 million (compared to US$144 million in the first half of the prior financial year) Total debt to capital ratio of 11% and cash reserves of US$932 million as of 30 September 2025 Interim dividend 17 HK cents per share (2.18 US cents per share) HONG KONG SAR - Media OutReach Newswire - 12 November 2025 – Johnson Electric Holdings Limited ("Johnson Electric"), a global leader in electric motors and motion subsystems, today announced its results for the six months ended 30 September 2025. Total group sales for the first half of the 2025/26 financial year totalled US$1,833 million, a decrease of 1% over the first half of the prior financial year. Excluding the effect of foreign exchange rate changes, sales declined by 2%. Net profit attributable to shareholders increased by 3% to US$133 million or 14.21 US cents per share on a fully diluted basis. Underlying net profit decreased by 8% to US$123 million. Automotive Products Group The Automotive Products Group ("APG"), which accounted for 84% of total Group sales in the period under review, reported a 3% decline in sales on a constant currency basis. On a regional basis, APG's constant currency sales were lower by 6% in Asia, 1% in the Americas, and 1% in Europe. The reduced level of sales achieved in the first half reflected the combination of price reductions for more mature product applications and APG's Sino-foreign joint venture OEM customers in China continuing to experience a significant loss in market share. Car production in Asia, dominated by China, now accounts for approximately 60 percent of global vehicle volume. Beyond its sheer size, the dynamism of China's auto sector is transforming the market domestically and, increasingly, globally. Government subsidies, expanding charging infrastructure, and aggressive pricing among the more than 100 brands of electric vehicles have fuelled a structural shift to electrification – with New Energy Vehicles (NEVs) amounting to over half of all passenger vehicles sold in China. Domestic OEM brands are leading this transformation, having almost doubled their market share in less than five years to over two-thirds of domestic sales. In the short term, APG has been negatively impacted by the rapid shift in automotive OEM market share, since a majority of its sales in China have historically been to Sino-foreign joint venture customers. However, encouraging progress is being made in winning new business from several leading domestic Chinese OEM customers who have found Johnson Electric to be a responsive and cost-competitive partner to support their future growth plans. Those plans include accelerating exports of "Made in China" vehicles, as well as establishing assembly plants elsewhere in the world that will produce a new generation of vehicles "Designed in China". As the newly awarded programs begin to ramp-up production in the second half of the financial year, APG is on track to return to growth. Outside of Asia, automotive industry demand over the period under review was relatively subdued. In Europe, consumer interest in NEVs remains strong, especially for plug-in hybrids, but concerns over job security and the comparatively higher price of NEVs are keeping buyers in check. The region's automakers are themselves faced with enormous structural challenges that include increased competition from Chinese brands who have taken five percent of the market, and excess production capacity that is forcing several OEMs to pause production in some plants and rethink their future vehicle roadmaps. North America's automotive sector is similarly navigating a turbulent landscape shaped by trade policy uncertainty, shifting consumer behaviour, and electrification trends. Earlier in the year, the market was lifted by a consumer rush to buy new cars to beat an expected tariff-induced price hike. Demand momentum has since softened, except for a brief boost to electric vehicle sales spurred by the expiry of a federal tax credit. Volatile tariff policies are also disrupting supply chains, requiring OEMs and their suppliers to reconfigure operations across the US, Canada, and Mexico. These changes are increasing costs, leading to higher vehicle prices and reduced affordability. APG's strategy in the context of this varied and highly unpredictable global operating environment remains, firstly, to focus on bringing to market innovative motion technologies that enable electrification, reduce emissions, and enhance passenger safety and comfort. Secondly, APG aims to offer its diverse base of customers an unrivalled total cost and value proposition that combines speed, scale, and reliability of production with an adaptable global operating footprint. Industry Products Group The Industry Products Group ("IPG"), which accounted for 16% of total Group sales, reported flat sales compared to the first half of the prior financial year on a constant currency basis. IPG's sales have stabilized after a difficult period of contraction that resulted from a softening in demand for discretionary hardware products (relative to services) in the post-pandemic era; and low pricing (rather than brand name, functionality, or reliability) increasingly becoming the key purchasing criteria for many consumers. Management has rationalized and consolidated its production to focus on application segments where it can leverage highly automated assembly lines and digital processes to be more cost competitive. Equally important, new business development has been redirected towards the rapidly growing base of Chinese manufacturers who are capturing an increasing share of the global market for consumer and commercial hardware goods – particularly for low-priced, entry-level products. Although the repositioning of IPG is still at an early stage, the division has secured several recent orders that give rise to optimism. In parallel to targeting high-volume, standardized motion product applications, IPG has continued to make progress in supplying motion subsystem solutions to more specialized, higher-growth segments, including warehouse automation, medical devices, semiconductor manufacturing equipment, and liquid cooling applications. Formation of PRC Joint Ventures to pursue opportunities in Humanoid Robotics In July 2025, the Group announced the formation of two joint venture companies with Shanghai Mechanical & Electrical Industry Co., Ltd, a leading Chinese industrial manufacturing company with extensive interests across a wide range of end markets. This new initiative has been established to enable the end-to-end delivery of high-performance humanoid robotic core components and subsystems to customers across the PRC. The two joint ventures are structured to complement one another – combining sales, business development and customer application support with product design, engineering, and manufacturing expertise. Gross Margins and Operating Profitability Gross profit margins increased slightly to 24.0% from 23.6%, primarily due to reduced direct labour costs, material cost deflation, and favourable foreign exchange rate movements that outweighed the effects of price reductions and wage inflation. Reported earnings before interest, tax and amortization ("EBITA") was flat at US$171 million. Adjusted to exclude non-cash foreign exchange rate movements and restructuring charges, EBITA was US$159 million or 8.7% of sales. Free Cash Flow and Financial Condition Free cash flow from operations increased to US$174 million from US$144 million, largely due to a reduction in working capital that more than offset an increase in capital expenditure. Capital expenditure levels in the near term are expected to remain at a high single-digit percentage of sales due to planned investments in automation and further development of the manufacturing footprint. The Group remains in a financially robust condition with a total debt to capital ratio of 11% and cash balances of US$932 million as of 30 September 2025. Interim Dividend The Board has today declared an interim dividend of 17 HK cents per share, equivalent to 2.18 US cents per share (2024/25 interim: 17 HK cents per share). The interim dividend will be payable on 6 January 2026 to shareholders registered on 9 December 2025. Chairman's Comments on the Half-Year Results and Outlook Commenting on the results, Dr. Patrick Wang, Chairman and Chief Executive, said, "Johnson Electric delivered stable financial results in the six-month period ended 30 September 2025, despite subdued macro-economic conditions and ongoing uncertainty concerning global trade tariffs." "Although the global economy is showing resilience in the face of the disruption caused by the radical shift in US international trade policy, overall consumer sentiment in the world's major economies has remained cautious due to cost of living concerns and softening labour markets. In Johnson Electric's primary end markets of automotive vehicles and consumer and industrial hardware products, the impact has been mixed. Favourable growth dynamics in several new motion application segments are being offset by sluggish growth of more mature products and by OEM customers delaying the launch of new programs due to ongoing uncertainties related to demand and global supply chain configurations." Regarding the outlook for the second half of the financial year, Dr. Patrick Wang commented, "The resilience of the global economy during the first half of the year belied a precarious environment for trade and investment that remains a significant concern for international manufacturing businesses. The new regime of higher US tariffs on imports from almost all countries is still unfolding and its impact on consumer behaviour, business confidence, and manufacturing supply chains is unclear." Dr. Patrick Wang further commented, "Notwithstanding the highly uncertain macro-economic outlook, Johnson Electric is cautiously optimistic that its sales in the second half of the financial year will improve modestly over the prior year. Over the medium and longer term – and assuming that the ongoing trade negotiations between the US and China result in a pragmatic agreement – the prospects for profitable growth are encouraging. Our product portfolio of innovative components and subsystems is uniquely well placed to help our customers solve their most critical motion-related problems. And we are continuing to invest in adapting and strengthening our operating model to provide security of supply to customers at the same time as delivering sustainable value creation for shareholders." Hashtag: #JohnsonElectricThe issuer is solely responsible for the content of this announcement.About Johnson Electric GroupThe Johnson Electric Group is a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components. It serves a broad range of industries including Automotive, Smart Metering, Medical Devices, Business Equipment, Home Automation, Ventilation, White Goods, Power Tools, and Lawn & Garden Equipment. The Group is headquartered in Hong Kong and employs over 30,000 individuals in over 20 countries worldwide. Johnson Electric Holdings Limited is listed on The Stock Exchange of Hong Kong Limited (Stock Code: 179). For further information, please visit: www.johnsonelectric.com. Forward Looking Statements This news release contains certain forward looking statements with respect to the financial condition, results of operations and business of Johnson Electric and certain plans and objectives of the management of Johnson Electric. Words such as "outlook", "expects", "anticipates", "intends", "plans", "believe", "estimates", "projects", variations of such words and similar expressions are intended to identify such forward looking statements. Such forward looking statements involve known and unknown risk, uncertainties and other factors which may cause the actual results or performance of Johnson Electric to be materially different from any future results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding Johnson Electric's present and future business strategies and the political and economic environment in which Johnson Electric will operate in the future.
GUANGZHOU, China, Nov. 12, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total net revenues increased by 9.8% to RMB1,688.3 million (US$237.1 million) for the third quarter of 2025, from RMB1,537.7 million for the same period of 2024. Game-related services, advertising and other revenues increased by 29.6% to RMB531.6 million (US$74.7 million) for the third quarter of 2025, from RMB410.2 million for the same period of 2024. Net income attributable to HUYA Inc. was RMB9.6 million (US$1.3 million) for the third quarter of 2025, compared with RMB23.6 million for the same period of 2024. Non-GAAP net income attributable to HUYA Inc.[1] was RMB36.3 million (US$5.1 million) for the third quarter of 2025, compared with RMB78.0 million for the same period of 2024. Average MAUs[2] for the third quarter of 2025 was 162.3 million. Mr. Junhong Huang, Acting Co-Chief Executive Officer and Senior Vice President of Huya, commented, "As we close the third quarter of 2025, we are encouraged to report that Huya has returned to a promising growth trajectory, with total net revenues up approximately 10% year-over-year. This progress reflects both stabilization in our live streaming revenues and accelerating contributions from game-related services, advertising and other initiatives. "Game-related services, advertising and other revenues grew approximately 30% year-over-year, accounting for over 30% of our total net revenues for the first time, marking a key milestone since our strategic transformation two years ago. In-game item sales have been a main driver of this segment as we deepened and expanded collaborations with game partners both in China and abroad," Mr. Huang concluded. Mr. Raymond Peng Lei, Acting Co-Chief Executive Officer and Chief Financial Officer of Huya, added, "We are pleased to see total net revenues re-accelerate and operating performance continue to improve in the third quarter. These results reflect our steady execution on revenue diversification and prudent cost management. Looking ahead, we will continue to explore opportunities in a measured way, pursuing growth thoughtfully while preserving earnings quality and building long-term shareholder value." Third Quarter 2025 Financial Results Total net revenues increased by 9.8% to RMB1,688.3 million (US$237.1 million) for the third quarter of 2025, from RMB1,537.7 million for the same period of 2024. Live streaming revenues increased by 2.6% to RMB1,156.7 million (US$162.5 million) for the third quarter of 2025, from RMB1,127.5 million for the same period of 2024, primarily due to the improvement of average spending per paying user for live streaming services. Game-related services, advertising and other revenues increased by 29.6% to RMB531.6 million (US$74.7 million) for the third quarter of 2025, from RMB410.2 million for the same period of 2024. The increase was primarily due to higher revenues from game-related services and advertising, which were mainly attributable to the Company's deepened cooperation with Tencent and other game companies. Cost of revenues increased by 9.6% to RMB1,461.6 million (US$205.3 million) for the third quarter of 2025 from RMB1,334.1 million for the same period of 2024, primarily due to increased revenue sharing fees and content costs as well as costs of in-game items, partially offset by decreased bandwidth and server custody fees. Revenue sharing fees and content costs, a key component of cost of revenues, increased by 7.8% year-over-year to RMB1,262.9 million (US$177.4 million) for the third quarter of 2025, primarily due to increased revenues. Gross profit increased by 11.3% to RMB226.6 million (US$31.8 million) for the third quarter of 2025, from RMB203.6 million for the same period of 2024. Gross margin was 13.4% for the third quarter of 2025, compared with 13.2% for the same period of 2024. Research and development expenses decreased by 2.8% to RMB121.9 million (US$17.1 million) for the third quarter of 2025 from RMB125.5 million for the same period of 2024, primarily due to decreased staff costs as a result of enhanced efficiency. Sales and marketing expenses decreased by 4.4% to RMB70.1 million (US$9.8 million) for the third quarter of 2025 from RMB73.3 million for the same period of 2024, primarily due to decreased channel promotion fees. General and administrative expenses increased by 15.4% to RMB57.7 million (US$8.1 million) for the third quarter of 2025 from RMB50.0 million for the same period of 2024, primarily due to increased professional service fees and staff costs. Other income was RMB8.9 million (US$1.2 million) for the third quarter of 2025, compared with RMB13.0 million for the same period of 2024, primarily due to lower government subsidies. Operating loss was RMB14.3 million (US$2.0 million) for the third quarter of 2025, compared with RMB32.3 million for the same period of 2024. Non-GAAP operating income was RMB6.3 million (US$0.9 million) for the third quarter of 2025, compared with non-GAAP operating loss of RMB13.2 million for the same period of 2024. Interest income was RMB34.7 million (US$4.9 million) for the third quarter of 2025, compared with RMB96.6 million for the same period of 2024, primarily due to a lower time deposit balance, which was mainly attributable to the special cash dividends paid. Net income attributable to HUYA Inc. was RMB9.6 million (US$1.3 million) for the third quarter of 2025, compared with RMB23.6 million for the same period of 2024. Non-GAAP net income attributable to HUYA Inc. was RMB36.3 million (US$5.1 million) for the third quarter of 2025, compared with RMB78.0 million for the same period of 2024. Basic and diluted net income per American depositary share ("ADS") were each RMB0.04 (US$0.01) for the third quarter of 2025. Basic and diluted net income per ADS were each RMB0.10 for the third quarter of 2024. Each ADS represents one Class A ordinary share of the Company. Non-GAAP basic and diluted net income per ADS were each RMB0.16 (US$0.02) for the third quarter of 2025. Non-GAAP basic and diluted net income per ADS were each RMB0.34 for the third quarter of 2024. As of September 30, 2025, the Company had cash and cash equivalents, short-term deposits and long-term deposits of RMB3,828.2 million (US$537.7 million), compared with RMB3,766.4 million as of June 30, 2025. Earnings Webinar The Company's management will host a Tencent Meeting Webinar at 5:00 a.m. U.S. Eastern Time on November 12, 2025 (6:00 p.m. Beijing/Hong Kong time on November 12, 2025), to review and discuss the Company's business and financial performance. For participants who wish to join the webinar, please complete the online registration in advance using the links provided below. Upon registration, participants will receive an email with webinar access information, including meeting ID, meeting link, dial-in numbers, and a unique attendee ID to join the webinar. Participant Online Registration: Chinese Mainland[3]: https://meeting.tencent.com/dw/aMWqwn0OAFE7 International: https://voovmeeting.com/dw/aMWqwn0OAFE7 A live webcast of the webinar will be accessible at https://ir.huya.com, and a replay of the webcast will be available following the session. [1] "Non-GAAP net income attributable to HUYA Inc." is defined as net income (loss) attributable to HUYA Inc. excluding share-based compensation expenses, gain arising from disposal of an equity investment, net of income taxes, impairment loss of investments, and amortization of intangible assets from business acquisitions, net of income taxes, to the extent applicable. For more information, please refer to the section titled "Use of Non-GAAP Financial Measures" and the table captioned "HUYA Inc. Unaudited Reconciliations of GAAP and Non-GAAP Results" at the end of this press release. [2] Refers to the average total monthly active users who accessed the Company's domestic and overseas platforms and services (primarily the domestic Huya Live platform, its global mobile application service platform, its overseas game live streaming platform, and related services), inclusive of users across all devices (mobile, PC and web). Average MAUs for any period is calculated by dividing (i) the sum of total active users for each month during such relevant period, by (ii) the number of months during such relevant period. The Company shifted to total MAU reporting starting from the second quarter of 2025 to provide a more comprehensive view of user activity, in line with its business expansion, cross-platform strategy, and overseas initiatives. [3] For the purpose of this announcement only, Chinese Mainland excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region of the People's Republic of China, and Taiwan. About HUYA Inc. HUYA Inc. is a leading game-related entertainment and services provider. Huya delivers dynamic live streaming and video content and a rich array of services spanning games, e-sports, and other interactive entertainment genres to a large, highly engaged community of game enthusiasts. Huya has cultivated a robust entertainment ecosystem powered by AI and other advanced technologies, serving users and partners across the gaming universe, including game companies, e-sports tournament organizers, broadcasters and talent agencies. Leveraging this strong foundation, Huya has also expanded into innovative game-related services, such as game distribution, in-game item sales, advertising and more. Huya continues to extend its footprint in China and abroad, meeting the evolving needs of gamers, content creators, and industry partners worldwide. For more information, please visit: https://ir.huya.com. Use of Non-GAAP Financial Measures The unaudited condensed consolidated financial information is prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"), except that the consolidated statement of changes in shareholders' equity, consolidated statements of cash flows, and the detailed notes have not been presented. Huya uses non-GAAP gross profit, non-GAAP operating income (loss), non-GAAP net income attributable to HUYA Inc., non-GAAP net income attributable to ordinary shareholders, non-GAAP basic and diluted net income per ordinary share, and non-GAAP basic and diluted net income per ADS, which are non-GAAP financial measures. Non-GAAP gross profit is gross profit excluding share-based compensation expenses allocated in cost of revenues. Non-GAAP operating income (loss) is operating loss excluding share-based compensation expenses and amortization of intangible assets from business acquisitions. Non-GAAP net income attributable to HUYA Inc. is net income (loss) attributable to HUYA Inc. excluding share-based compensation expenses, gain arising from disposal of an equity investment, net of income taxes, impairment loss of investments, and amortization of intangible assets from business acquisitions, net of income taxes, to the extent applicable. Non-GAAP net income attributable to ordinary shareholders is net income (loss) attributable to ordinary shareholders excluding share-based compensation expenses, gain arising from disposal of an equity investment, net of income taxes, impairment loss of investments, and amortization of intangible assets from business acquisitions, net of income taxes, to the extent applicable. Non-GAAP basic and diluted net income per ordinary share and per ADS is non-GAAP net income attributable to ordinary shareholders divided by the weighted average number of ordinary shares and ADS used in the calculation of non-GAAP basic and diluted net income per ordinary share and per ADS. The Company believes that separate analysis and exclusion of the impact of (i) share-based compensation expenses, (ii) gain arising from disposal of an equity investment, net of income taxes, (iii) impairment loss of investments, and (iv) amortization of intangible assets from business acquisitions (net of income taxes), add clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting and measuring results against the forecast. The Company believes that non-GAAP financial measures represent useful supplemental information for investors and analysts to assess its operating performance without the effect of (i) share-based compensation expenses, and (ii) amortization of intangible assets from business acquisitions (net of income taxes), which have been and will continue to be significant recurring expenses in its business, and (iii) gain arising from disposal of an equity investment, net of income taxes, and (iv) impairment loss of investments, which may recur when there is observable price change in the future. However, the use of non-GAAP financial measures has material limitations as an analytical tool. One of the limitations of using non-GAAP financial measures is that they do not include all items that impact the Company's net income (loss) for the period. In addition, because non-GAAP financial measures are not measured in the same manner by all companies, they may not be comparable to other similarly titled measures used by other companies. In light of the foregoing limitations, you should not consider a non-GAAP financial measure in isolation from or as an alternative to the financial measures prepared in accordance with U.S. GAAP. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, or as a substitute for, the financial information prepared and presented in accordance with U.S. GAAP. For more information on these non-GAAP financial measures, please see the table captioned "HUYA Inc. Unaudited Reconciliations of GAAP and Non-GAAP Results" at the end of this announcement. Exchange Rate Information This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1190 to US$1.00, the noon buying rate in effect on September 30, 2025, in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollar amounts referred to in this announcement could have been or could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this announcement, as well as Huya's strategic and operational plans, contain forward-looking statements. Huya may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Huya's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Huya's goals and strategies; Huya's future business development, results of operations and financial condition; the expected growth of the live streaming market and game market; the expectation regarding the rate at which to gain active users, especially paying users; Huya's ability to monetize the user base; Huya's efforts in complying with applicable data privacy and security regulations; fluctuations in general economic and business conditions in China; the economy in China and elsewhere generally; any regulatory developments in laws, regulations, rules, policies or guidelines applicable to Huya; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Huya's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Huya does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: In China: HUYA Inc.Investor RelationsTel: +86-20-2290-7829E-mail: ir@huya.com Piacente Financial CommunicationsJenny CaiTel: +86-10-6508-0677E-mail: huya@tpg-ir.com In the United States: Piacente Financial Communications Brandi PiacenteTel: +1-212-481-2050E-mail: huya@tpg-ir.com HUYA INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands, except share, ADS, per share data and per ADS data) As of December 31, As of September 30, 2024 2025 2025 RMB RMB US$ Assets Current assets Cash and cash equivalents 1,188,911 725,818 101,955 Restricted cash 17,031 9,107 1,279 Short-term deposits 4,075,048 3,042,408 427,365 Accounts receivable, net 76,044 164,647 23,128 Prepaid assets and amounts due from related parties, net 207,565 391,211 54,953 Prepayments and other current assets, net 523,674 579,821 81,447 Total current assets 6,088,273 4,913,012 690,127 Non-current assets Long-term deposits 1,470,000 60,000 8,428 Investments 440,790 393,639 55,294 Goodwill 463,796 458,447 64,398 Property and equipment, net 484,008 550,873 77,381 Intangible assets, net 153,190 133,263 18,719 Right-of-use assets, net 339,492 311,464 43,751 Prepayments and other non-current assets 128,262 15,749 2,212 Total non-current assets 3,479,538 1,923,435 270,183 Total assets 9,567,811 6,836,447 960,310 Liabilities and shareholders' equity Current liabilities Accounts payable 66,613 235,391 33,065 Advances from customers and deferred revenue 265,628 226,512 31,818 Income taxes payable 54,594 59,193 8,315 Accrued liabilities and other current liabilities 1,360,949 1,006,309 141,356 Amounts due to related parties 161,529 177,154 24,885 Lease liabilities due within one year 28,581 22,015 3,092 Total current liabilities 1,937,894 1,726,574 242,531 Non-current liabilities Lease liabilities 20,047 2,946 414 Deferred tax liabilities 23,405 20,148 2,830 Deferred revenue 35,786 32,647 4,586 Total non-current liabilities 79,238 55,741 7,830 Total liabilities 2,017,132 1,782,315 250,361 HUYA INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED) (All amounts in thousands, except share, ADS, per share data and per ADS data) As of December 31, As of September 30, 2024 2025 2025 RMB RMB US$ Shareholders' equity Class A ordinary shares (US$0.0001 par value; 750,000,000 shares authorized as of December 31, 2024 and September 30, 2025, respectively; 74,845,398 and 73,019,089 shares issued and outstanding as of December 31, 2024 and September 30, 2025, respectively) 52 53 7 Class B ordinary shares (US$0.0001 par value; 200,000,000 shares authorized as of December 31, 2024 and September 30, 2025, respectively; 150,386,517 and 150,386,517 shares issued and outstanding as of December 31, 2024 and September 30, 2025, respectively) 98 98 14 Treasury shares (108,101) (142,299) (19,989) Additional paid-in capital 8,866,492 6,452,211 906,337 Statutory reserves 122,429 122,429 17,197 Accumulated deficit (2,100,291) (2,095,349) (294,332) Accumulated other comprehensive income 770,000 716,989 100,715 Total shareholders' equity 7,550,679 5,054,132 709,949 Total liabilities and shareholders' equity 9,567,811 6,836,447 960,310 HUYA INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (All amounts in thousands, except share, ADS, per share data and per ADS data) Three Months Ended Nine Months Ended September 30, 2024 June 30, 2025 September 30, 2025 September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2025 RMB RMB RMB US$ RMB RMB US$ Net revenues Live streaming 1,127,499 1,153,232 1,156,681 162,478 3,621,007 3,448,064 484,347 Game-related services, advertising and others 410,160 413,857 531,570 74,669 962,281 1,315,861 184,838 Total net revenues 1,537,659 1,567,089 1,688,251 237,147 4,583,288 4,763,925 669,185 Cost of revenues(1) (1,334,085) (1,354,771) (1,461,627) (205,314) (3,944,297) (4,136,500) (581,051) Gross profit 203,574 212,318 226,624 31,833 638,991 627,425 88,134 Operating expenses(1) Research and development expenses (125,508) (122,156) (121,942) (17,129) (389,324) (373,623) (52,483) Sales and marketing expenses (73,330) (57,699) (70,107) (9,848) (211,251) (188,501) (26,479) General and administrative expenses (50,025) (63,743) (57,729) (8,109) (173,786) (182,917) (25,694) Total operating expenses (248,863) (243,598) (249,778) (35,086) (774,361) (745,041) (104,656) Other income, net 12,958 7,577 8,854 1,244 38,486 19,965 2,804 Operating loss (32,331) (23,703) (14,300) (2,009) (96,884) (97,651) (13,718) Interest income 96,580 59,074 34,655 4,868 316,155 158,645 22,285 Impairment loss of investments (36,298) (30,000) (8,698) (1,222) (81,377) (38,698) (5,436) Disposal gain of investments - - 1,500 211 - 1,500 211 Foreign currency exchange losses, net (1,225) (2,112) (2,008) (282) (3,280) (4,536) (637) Income before income tax expenses 26,726 3,259 11,149 1,566 134,614 19,260 2,705 Income tax expenses (3,113) (7,388) (508) (71) (10,366) (11,144) (1,565) Income (loss) before loss in equity method investments, net of income taxes 23,613 (4,129) 10,641 1,495 124,248 8,116 1,140 Loss in equity method investments, net of income taxes - (1,362) (1,085) (152) - (3,124) (439) Net income (loss) attributable to HUYA Inc. 23,613 (5,491) 9,556 1,343 124,248 4,992 701 Net income (loss) attributable to ordinary shareholders 23,613 (5,491) 9,556 1,343 124,248 4,992 701 HUYA INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (CONTINUED) (All amounts in thousands, except share, ADS, per share data and per ADS data) Three Months Ended Nine Months Ended September 30, 2024 June 30, 2025 September 30, 2025 September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2025 RMB RMB RMB US$ RMB RMB US$ Net income (loss) per ordinary share —Basic 0.10 (0.02) 0.04 0.01 0.54 0.02 0.00 —Diluted 0.10 (0.02) 0.04 0.01 0.53 0.02 0.00 Net income (loss) per ADS* —Basic 0.10 (0.02) 0.04 0.01 0.54 0.02 0.00 —Diluted 0.10 (0.02) 0.04 0.01 0.53 0.02 0.00 Weighted average number of ADS used in calculating net income (loss) per ADS —Basic 231,366,502 227,675,862 229,032,506 229,032,506 231,852,981 228,715,412 228,715,412 —Diluted 232,948,154 227,675,862 231,210,726 231,210,726 234,514,598 231,084,419 231,084,419 * Each ADS represents one Class A ordinary share. (1) Share-based compensation was allocated in cost of revenues and operating expenses as follows: Three Months Ended Nine Months Ended September 30, 2024 June 30, 2025 September 30, 2025 September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2025 RMB RMB RMB US$ RMB RMB US$ Cost of revenues 3,521 3,707 1,666 234 12,298 8,756 1,230 Research and development expenses 5,497 6,563 4,335 609 20,986 17,211 2,418 Sales and marketing expenses 171 394 213 30 983 927 130 General and administrative expenses 4,014 7,385 8,435 1,185 12,855 23,868 3,353 HUYA INC. UNAUDITED RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except share, ADS, per share data and per ADS data) Three Months Ended Nine Months Ended September 30, 2024 June 30, 2025 September 30, 2025 September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2025 RMB RMB RMB US$ RMB RMB US$ Gross profit 203,574 212,318 226,624 31,833 638,991 627,425 88,134 Share-based compensation expenses allocated in cost of revenues 3,521 3,707 1,666 234 12,298 8,756 1,230 Non-GAAP gross profit 207,095 216,025 228,290 32,067 651,289 636,181 89,364 Operating loss (32,331) (23,703) (14,300) (2,009) (96,884) (97,651) (13,718) Share-based compensation expenses 13,203 18,049 14,649 2,058 47,122 50,762 7,131 Amortization of intangible assets from business acquisitions 5,937 6,005 5,958 837 17,808 17,959 2,523 Non-GAAP operating (loss) income (13,191) 351 6,307 886 (31,954) (28,930) (4,064) Net income (loss) attributable to HUYA Inc. 23,613 (5,491) 9,556 1,343 124,248 4,992 701 Gain arising from disposal of an equity investment, net of income taxes - - (1,500) (211) - (1,500) (211) Impairment loss of investments 36,298 30,000 8,698 1,222 81,377 38,698 5,436 Share-based compensation expenses 13,203 18,049 14,649 2,058 47,122 50,762 7,131 Amortization of intangible assets from business acquisitions, net of income taxes 4,928 4,984 4,945 695 14,781 14,906 2,094 Non-GAAP net income attributable to HUYA Inc. 78,042 47,542 36,348 5,107 267,528 107,858 15,151 Net income (loss) attributable to ordinary shareholders 23,613 (5,491) 9,556 1,343 124,248 4,992 701 Gain arising from disposal of an equity investment, net of income taxes - - (1,500) (211) - (1,500) (211) Impairment loss of investments 36,298 30,000 8,698 1,222 81,377 38,698 5,436 Share-based compensation expenses 13,203 18,049 14,649 2,058 47,122 50,762 7,131 Amortization of intangible assets from business acquisitions, net of income taxes 4,928 4,984 4,945 695 14,781 14,906 2,094 Non-GAAP net income attributable to ordinary shareholders 78,042 47,542 36,348 5,107 267,528 107,858 15,151 Non-GAAP net income per ordinary share —Basic 0.34 0.21 0.16 0.02 1.15 0.47 0.07 —Diluted 0.34 0.21 0.16 0.02 1.14 0.47 0.07 Non-GAAP net income per ADS —Basic 0.34 0.21 0.16 0.02 1.15 0.47 0.07 —Diluted 0.34 0.21 0.16 0.02 1.14 0.47 0.07 Weighted average number of ADS used in calculating Non-GAAP net income per ADS —Basic 231,366,502 227,675,862 229,032,506 229,032,506 231,852,981 228,715,412 228,715,412 —Diluted 232,948,154 230,562,291 231,210,726 231,210,726 234,514,598 231,084,419 231,084,419
Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter HONG KONG, Nov. 12, 2025 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial results, highlighted by IM8's trajectory towards $120 million in annualized recurring revenue ("ARR") in just 12 months by December 2025. This unprecedented growth positions IM8 as having the fastest growth trajectory ever recorded in the global supplements industry, outpacing several leading AI startups. The record-breaking performance comes on the heels of Prenetics' successful $44 million equity offering completed in October 2025, which attracted high-quality strategic investors including Kraken, Exodus (NYSE: EXOD), XtalPi (2228.HK), DL Holdings (1709.HK), Jihan Wu's GPTX, and World No. 1 tennis champion Aryna Sabalenka, positioning the Company for accelerated global expansion. IM8: Redefining Industry Growth Standards with Global Reach IM8's extraordinary trajectory reached new heights in October 2025, delivering approximately $9.0 million in monthly revenue – representing 36% month-over-month growth from September's $6.6 million. With this momentum, IM8 is on track to achieve $10 million in monthly revenue by December 2025, translating to a $120 million ARR run rate in just 12 months from launch. The brand has achieved truly global scale with 420,000+ customer purchases across 31 countries worldwide. International markets now represent 56.5% of IM8's revenue, with the top five markets being: United States (43.5% of revenue) Canada United Kingdom Australia Singapore In line with our growth trajectory, we are introducing key performance indicators to track and communicate our performance more effectively. IM8 - Key Performance Indicators (Q3 2025 vs Q2 2025, unless otherwise indicated) Metric Q3 2025 Q2 2025 Growth Monthly Revenue (End of Period) $6.6 million $4.5 million +47 % Quarterly Revenue $17.2 million $9.8 million +76 % Total Customer Orders 160,000+ 90,000+ +78 % Total Servings Delivered 4.8 million+ 2.7 million+ +78 % New Customer Average Order Value $150 (October) $110 +36 % New Customer Subscription Rate ~80% ~80% Maintained Gross Margin ~60% ~52% +8 % Payback Period 3.9 Months N/A N/A Countries Served 41 (from November) 31 +10 countries Danny Yeung, Chief Executive Officer and Co-Founder, commented: "After three full quarters of IM8 data, I have never been more confident in our trajectory. The growth has been nothing short of phenomenal – from $581,000 in monthly revenue at launch to $10 million by December, representing a 1,600%+ increase in just 12 months. Every key metric reinforces this momentum: 36% month-over-month growth, ~80% subscription rates, $150 average order value, ~60% gross margin, and a remarkable 3.9-month customer payback period that demonstrates the exceptional unit economics of our premium health and longevity platform. Break-even and profitability is clearly in sight. Our adjusted EBITDA loss has dramatically improved from $(4.5) million in Q1 2025[2], to $(4.1) million in Q2 2025, and now to just $(2.1) million in Q3 2025. This trend proves we could be profitable if we wanted to, but given the immense global opportunity we have, we will look to strategically scale even more aggressively. Our balance sheet has never been stronger. With approximately $120 million in total liquidity, zero debt, and the recent $44 million funding round from high-caliber investors, we have the financial foundation to aggressively scale this extraordinary trajectory without dilutive capital needs. This financial strength allows us to double down on growth, knowing our unit economics are proven. With our momentum and growth levers, $300 million ARR by year-end 2026 is in sight. We believe we can be the next Hims & Hers because we are following a similar direct-to-consumer playbook with strong unit economics, premium positioning, and subscription-based recurring revenue. Combined with our Bitcoin treasury providing strategic optionality, we are positioning shareholders to benefit from two of the most transformative secular trends of our time. The next 12 months will demonstrate why Prenetics represents a generational investment opportunity. For a deeper dive into our vision and strategy, I encourage investors to read my first-ever shareholder letter at https://www.prenetics.com/q3ceo." Third Quarter 2025 Financial Performance Highlights:[3] Revenue of $23.6 million in the third quarter of 2025, an increase of 567.7% as compared to the third quarter of 2024. Gross profit of $14.0 million in the third quarter of 2025, an increase of 631.2% as compared to the third quarter of 2024. Adjusted EBITDA[4] loss of $(2.1) million in the third quarter of 2025, a decrease of 49.6% as compared to adjusted EBITDA loss of $(4.3) million in the third quarter of 2024, a decrease of 49.6% as compared to adjusted EBITDA loss of $(4.1) million in the second quarter of 2025 and a decrease of 54.0% as compared to adjusted EBITDA loss of $(4.5) million in the first quarter of 2025. Loss of $(6.8) million in the third quarter of 2025, an improvement of 31.2% as compared to the third quarter of 2024. Adjusted current assets[5] were $84.6 million, including $59.6 million of adjusted cash[6] as of September 30, 2025. As of September 30, 2025, the Company held 248.42 Bitcoin[7] with a value of $28.3 million and remained debt-free. As of October 31, 2025, the Company's cash and cash escrow balance increased to $82 million and Bitcoin holdings increased to 377.42 Bitcoin valued at $41.3 million. The increase is primarily a result of $44 million fundraising, completed in October 2025. Third Quarter 2025 Revenue by Business Unit: IM8: $17.2 million (increase of 76% over Q2 2025) Europa: $4.0 million CircleDNA: $2.4 million Total: $23.6 million Nine Months Ended September 30, 2025 Financial Performance Highlights: Revenue of $55.8 million in the nine months ended September 30, 2025, an increase of 495.6% as compared to the nine months ended September 30, 2024. Gross profit of $27.2 million in the nine months ended September 30, 2025, an increase of 296.3% as compared to the nine months ended September 30, 2024. Adjusted EBITDA loss of $(10.7) million in the nine months ended September 30, 2025, an increase of 4.9% as compared to the nine months ended September 30, 2024. Loss of $(26.6) million in the nine months ended September 30, 2025, an increase of 6.0% as compared to the nine months ended September 30, 2024. Nine Months Ended September 30, 2025 Revenue by Business Unit: IM8: $32.7 million Europa: $16.0 million CircleDNA: $7.1 million Total: $55.8 million Liquidity With approximately $120 million in total liquidity, including approximately $82 million in cash and cash escrow, and 387 BTC (valued at approximately $41 million), Prenetics maintains a debt-free balance sheet that provides substantial runway for continued growth and strategic Bitcoin accumulation. This strong financial foundation, enhanced by the recent equity offering, positions the Company to capitalize on IM8's momentum without dilutive capital needs. Bitcoin Treasury Strategy As part of its pioneering dual-engine strategy, Prenetics has expanded its Bitcoin treasury to 387 BTC valued at approximately $41 million. Prenetics continues to execute its disciplined "1 BTC per day" accumulation strategy, reinforcing its long-term conviction in Bitcoin as a strategic treasury asset. This positions Prenetics as the only NASDAQ-listed consumer healthcare company to integrate Bitcoin as a strategic treasury asset, providing shareholders exposure to both the explosive growth in the wellness market and the digital asset transformation. The Company's Bitcoin accumulation strategy, as detailed in CEO Danny Yeung's comprehensive manifesto "The Dual Engine Revolution," represents a disciplined approach to building long-term shareholder value through diversified asset holdings. The manifesto can be found at https://prenetics.com/manifesto and the Company's real-time Bitcoin holdings can be found here at https://prenetics.com/btc. Strategic Portfolio Optimization Prenetics has initiated a comprehensive strategic review of non-core assets, including Europa Sports Partners, CircleDNA, and Insighta, as part of its focused capital allocation strategy. The Company expects to make an announcement regarding Europa Sports Partners in the coming weeks, reflecting the advanced stage of discussions for this asset. This proactive approach aims to unlock shareholder value by concentrating resources on IM8, the Company's highest-growth and highest-margin business unit. The strategic review reflects Prenetics' commitment to operational excellence and capital efficiency following the successful $72 million divestiture of ACT Genomics. These initiatives position the Company to maximize returns on its core health and longevity platform while maintaining financial flexibility for strategic opportunities. Financial Outlook Prenetics reaffirms its full-year 2025 revenue guidance of $90 to $100 million (full-year 2025 revenue for IM8 expected to be $60 million). The Company provides Q4 2025 revenue guidance for IM8 of $28 million, which is expected to result in a 63% quarter-over-quarter increase as compared to Q3 2025. The Company reaffirms IM8 revenue is expected to be between $180 to $200 million for full-year 2026, which would translate to approximately $25 million in monthly revenue or $300 million ARR by the end of 2026. This growth will be driven by continued international expansion, new product innovations, and enhanced marketing initiatives across multiple sports and wellness verticals. Q3 2025 Earnings Conference Call The Company held its first ever earnings conference call on November 10, 2025 at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call concluded with a Q&A session with analysts. Date: Monday, November 10, 2025 Time: 8:30 a.m. Eastern Time Dial-in: 1-844-425-9470 International Dial-in: 201-298-0878 Webcast PRE Conference Call An audio replay of the webcast is available on the Company's investor relations website at https://ir.prenetics.com/. [1] "ARR" refers to annualized recurring revenue, which is is a non-IFRS financial measure calculated by multiplying the monthly revenue from a given month by 12. Refer to "Unaudited Non-IFRS Financial Measures" for more details regarding the Company's use of this non-IFRS financial measure. [2] Adjusted EBITDA loss in Q1 2025 as presented in this press release has been restated to reflect adjusted EBITDA loss from continuing operations, normalized to exclude ACT Genomics. Refer to the section titled "Basis of Presentation" for further details on the divestment of ACT Genomics and related IFRS Accounting Standards. [3] Unless otherwise specified, financial figures in this press release denotes results from continuing operations, which excludes our divested ACT Genomics. Refer to the section titled "Basis of Presentation" for further details on the divestment of ACT Genomics and related IFRS Accounting Standards. [4] Adjusted EBITDA is a non-IFRS financial measure defined as loss for the period excluding (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) non-recurring expenses related to acquisition, disposal and fundraising, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax. These adjustments are made for items that may not be indicative of our business performance, including non-cash and/or non-recurring items. Refer to "Reconciliation of loss for the period under IFRS and adjusted EBITDA (Non-IFRS)" for a reconciliation of adjusted EBITDA to loss for the period, the most comparable IFRS financial measure. [5] Adjusted current assets is a non-IFRS financial measure and represents current assets of $38.3 million as of September 30, 2025, including estimated proceeds from the divestment of ACT Genomics in the form of $46.3 million to be settled in cash, cash and cash equivalents totaling $13.3 million, financial assets at fair value through profit or loss of $10.5 million, and trade receivables of $1.8 million, amongst other accounting line items under current assets as of September 30, 2025. Refer to "Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)" for a reconciliation of adjusted current assets to current assets, the most comparable IFRS financial measure. [6] Adjusted cash is a non-IFRS financial measure and represents estimated proceeds from the divestment of ACT Genomics in the form of $46.3 million to be settled in cash, and cash and cash equivalents totaling $13.3 million as of September 30, 2025. Refer to "Unaudited Non-IFRS Financial Measures" for more details regarding the Company's use of this non-IFRS financial measure. [7] Bitcoin is classified as a non-current intangible asset under IFRS Accounting Standards. Bitcoin holdings value is as of September 30, 2025. About PreneticsPrenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $108 million in ARR within 11 months of launch, outpacing even leading AI startups. As the first consumer health company to establish a Bitcoin treasury, Prenetics continues to pioneer at the intersection of health innovation and digital assets, purchasing 1 Bitcoin per day, now totaling 387 BTC. About IM8IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8's flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com. Forward-Looking Statements This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including revenue ranges and breakdown timing) reflects management's current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," "guidance," "outlook," "forecast," or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: future alpha-generating activities involving the Company's Bitcoin holdings could expose it to additional risks; the Company's purchase of Bitcoin subjects it to risks related to extreme volatility and speculative nature of Bitcoin; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers' expectations; the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Basis of PresentationFigures for prior periods have been re-presented in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In June 2025, the Group determined that ACT Genomics Holdings Company Limited met the criteria to be classified as held for sale and a discontinued operation, following the signing of a definitive sale and purchase agreement with Delta Electronics, Inc. Under IFRS 5, the results of ACT Genomics are presented separately from the Group's continuing operations (comprising IM8, CircleDNA and Europa), and comparative figures have been restated accordingly. The divestment was completed on October 1, 2025, with ACT Genomics now fully excluded from Prenetics' continuing results. Unaudited non-IFRS financial measures have been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Non-IFRS Financial Measures". Unaudited Non-IFRS Financial MeasuresTo supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing the following non-IFRS measures: annualized recurring revenue, adjusted EBITDA, adjusted current assets, adjusted cash and revenue by business unit. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends. Management is excluding from some or all of its non-IFRS results (1) depreciation and amortization, (2) interest income, (3) other finance costs, (4) income tax (credit)/expense, (5) amortization of deferred expenses, (6) equity-settled share-based payment expenses, (7) non-recurring expenses related to acquisition, disposal and fundraising, (8) strategic realignment and discontinued products impact, (9) exchange gain or loss, net, (10) fair value loss on financial assets at fair value through profit or loss, (11) fair value loss on warrant liabilities, (12) share of loss of equity-accounted investees, net of tax, and (13) loss from discontinued operation, net of tax — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures. In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management, or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss for the period under IFRS and adjusted EBITDA loss (Non-IFRS)" and "Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS)" set forth at the end of this document. PRENETICS GLOBAL LIMITEDUnaudited consolidated statements of financial position(All amounts in thousands of U.S. dollars ("$")) September 30, June 30, December 31, 2025 2025 2024 Assets Property, plant and equipment $ 2,212 $ 2,744 $ 3,780 Intangible assets 170 273 488 Cryptocurrency assets 28,334 20,285 — Goodwill 8,194 8,194 8,194 Interests in equity-accounted investees 66,265 66,693 67,396 Financial assets at fair value through profit or loss 1,103 1,103 1,103 Other non-current assets 452 449 451 Non-current assets 106,730 99,741 81,412 Deferred expenses — — 3,549 Inventories 5,341 4,297 4,736 Trade receivables 1,787 1,845 1,372 Deposits, prepayments and other receivables 7,418 8,151 7,488 Amount due from a disposal group — 2,012 2,630 Amount due from a related company 4 21 3 Financial assets at fair value through profit or loss 10,462 10,462 10,562 Cash and cash equivalents 13,264 17,249 45,406 Current assets 38,276 44,037 75,746 Assets classified as held for sale 51,501 55,328 59,044 Total assets $ 196,507 $ 199,106 $ 216,202 Liabilities Deferred tax liabilities $ 5 $ 5 $ 25 Warrant liabilities 779 875 175 Lease liabilities 679 1,048 1,760 Other non-current liabilities 230 228 230 Non-current liabilities 1,693 2,156 2,190 Trade payables 5,920 4,958 2,007 Accrued expenses and other current liabilities 10,727 8,692 7,099 Contract liabilities 7,205 6,623 6,475 Lease liabilities 1,426 1,526 1,691 Tax payable — 13 13 Current liabilities 25,278 21,812 17,285 Liabilities associated with assets classified as held for sale 8,334 24,246 25,370 Total liabilities 35,305 48,214 44,845 Equity Share capital 21 20 19 Reserves 118,104 119,880 137,754 Amounts recognized in other comprehensive income and accumulated in equity relating to assets classified as held for sale 43,167 31,082 33,673 Total equity attributable to equity shareholders of the Company 161,292 150,982 171,446 Non-controlling interests (90) (90) (89) Total equity 161,202 150,892 171,357 Total equity and liabilities $ 196,507 $ 199,106 $ 216,202 PRENETICS GLOBAL LIMITEDUnaudited consolidated statements of profit or loss and other comprehensive income(All amounts in thousands of U.S. dollars ("$") unless otherwise indicated) Nine Months Ended September 30, September 30, 2025 2024 (Restated) Continuing operations Revenue $ 55,832 $ 9,374 Direct costs (28,630) (2,509) Gross profit 27,202 6,865 Other income and other net gain 402 930 Selling and distribution expenses[6] (19,449) (3,837) Research and development expenses[6] (4,389) (6,943) Administrative and other operating expenses[6] (28,357) (21,005) Loss from operations (24,591) (23,990) Fair value loss on financial assets at fair value through profit or loss (100) (141) Fair value (loss)/gain on warrant liabilities (604) 18 Share of loss of equity-accounted investees (1,064) (1,049) Other finance costs (196) (82) Loss before taxation (26,555) (25,244) Income tax credit 4 199 Loss from continuing operations (26,551) (25,045) Discontinued operation Loss from discontinued operation, net of tax[7] (5,884) (7,219) Loss for the period (32,435) (32,264) Other comprehensive (expense)/income for the period Items that will not be reclassified subsequently to profit or loss: Share of other comprehensive income of equity-accounted investees (66) — Gain on revaluation of intangible assets 1,351 — Item that may be reclassified subsequently to profit or loss: Exchange difference on translation of foreign operations 388 (296) Total comprehensive expense for the period $ (30,762) $ (32,560) Loss attributable to: Equity shareholders of Prenetics $ (30,208) $ (29,962) Non-controlling interests (2,227) (2,302) $ (32,435) $ (32,264) Total comprehensive expense attributable to: Equity shareholders of Prenetics $ (28,567) $ (30,178) Non-controlling interests (2,195) (2,382) $ (30,762) $ (32,560) Loss per share: Basic (2.26) (2.42) Diluted (2.26) (2.42) Loss per share - Continuing operations: Basic (1.90) (2.02) Diluted (1.90) (2.02) Weighted average number of common shares: Basic 13,385,463 12,388,243 Diluted 13,385,463 12,388,243 PRENETICS GLOBAL LIMITEDUnaudited consolidated statements of profit or loss and other comprehensive income(All amounts in thousands of U.S. dollars ("$") unless otherwise indicated) Three Months Ended September 30, June 30, September 30, 2025 2025 2024 (Restated) Continuing operations Revenue $ 23,555 $ 17,680 $ 3,528 Direct costs (9,531) (10,391) (1,610) Gross profit 14,024 7,289 1,918 Other income and other net gain 395 (196) (171) Selling and distribution expenses[6] (9,859) (5,457) (1,086) Research and development expenses[6] (1,170) (1,212) (2,143) Administrative and other operating expenses[6] (9,554) (10,489) (8,035) Loss from operations (6,164) (10,065) (9,517) Fair value loss on financial assets at fair value through profit or loss — (100) — Fair value gain/(loss) on warrant liabilities 96 (637) 105 Share of loss of equity-accounted investees (656) (87) (379) Other finance costs (55) (65) (63) Loss before taxation (6,779) (10,954) (9,854) Income tax (expense)/credit (9) 33 (9) Loss from continuing operations (6,788) (10,921) (9,863) Discontinued operation Loss from discontinued operation, net of tax[7] (1,905) (1,806) (2,204) Loss for the period (8,693) (12,727) (12,067) Other comprehensive (expense)/income for the period Items that will not be reclassified subsequently to profit or loss: Share of other comprehensive income/(expense) of equity-accounted investees 228 (258) — Gain on revaluation of intangible assets 1,066 285 — Item that may be reclassified subsequently to profit or loss: Exchange difference on translation of foreign operations (9) 294 474 Total comprehensive expense for the period $ (7,408) $ (12,406) $ (11,593) Loss attributable to: Equity shareholders of Prenetics $ (7,408) $ (12,410) $ (10,672) Non-controlling interests (1,285) (317) (1,395) $ (8,693) $ (12,727) $ (12,067) Total comprehensive expense attributable to: Equity shareholders of Prenetics $ (6,144) $ (12,180) $ (10,252) Non-controlling interests (1,264) (226) (1,341) $ (7,408) $ (12,406) $ (11,593) Loss per share: Basic $ (0.53) $ (0.94) $ (0.84) Diluted (0.53) (0.94) (0.84) Loss per share - Continuing operations: Basic (0.41) (0.82) (0.78) Diluted (0.41) (0.82) (0.78) Weighted average number of common shares: Basic 13,895,394 13,247,315 12,722,810 Diluted 13,895,394 13,247,315 12,722,810 PRENETICS GLOBAL LIMITEDUnaudited Non-IFRS Financial Measures(All amounts in thousands of U.S. dollars ("$")) Reconciliation of loss for the period under IFRS and adjusted EBITDA (Non-IFRS) Nine Months Ended September 30, September 30, 2025 2024 (Restated) Loss for the period under IFRS $ (32,436) $ (32,264) Depreciation and amortization 1,848 1,812 Interest income (833) (1,441) Other finance costs 196 82 Income tax credit (4) (199) EBITDA under IFRS (31,229) (32,010) Amortization of deferred expenses 3,549 6,195 Equity-settled share-based payment expenses 5,054 4,665 Non-recurring expenses related to acquisition, disposal and fundraising 3,587 1,824 Strategic realignment and discontinued products impact 11 163 Exchange gain or loss, net 638 539 Fair value loss on financial assets at fair value through profit or loss 100 141 Fair value loss/(gain) on warrant liabilities 604 (18) Share of loss of equity-accounted investees, net of tax 1,064 1,049 Loss from discontinued operation, net of tax 5,884 7,219 Adjusted EBITDA (Non-IFRS) $ (10,738) $ (10,233) Three Months Ended September 30, June 30, September 30, 2025 2025 2024 (Restated) Loss for the period under IFRS $ (8,693) $ (12,727) $ (12,067) Depreciation and amortization 599 617 501 Interest income (102) (309) (394) Other finance costs 55 65 63 Income tax (credit)/expense 9 (33) 9 EBITDA under IFRS (8,132) (12,387) (11,888) Amortization of deferred expenses — 1,492 2,062 Equity-settled share-based payment expenses 2,000 1,887 1,346 Non-recurring expenses related to acquisition, disposal and fundraising 1,788 1,674 1,026 Strategic realignment and discontinued products impact — 8 125 Exchange gain or loss, net (204) 564 572 Fair value loss on financial assets at fair value through profit or loss — 100 — Fair value (gain)/loss on warrant liabilities (96) 637 (105) Share of loss of equity-accounted investees, net of tax 656 87 379 Loss from discontinued operation, net of tax 1,905 1,806 2,204 Adjusted EBITDA (Non-IFRS) $ (2,083) $ (4,132) $ (4,279) PRENETICS GLOBAL LIMITEDUnaudited Non-IFRS Financial Measures(All amounts in thousands of U.S. dollars ("$")) Revenue by business unit from continuing operations (Non-IFRS) Nine Months Ended September 30, September 30, 2025 2024 (Restated) Continuing operations CircleDNA $ 7,105 $ 7,708 IM8 32,701 — Europa 16,026 1,666 $ 55,832 $ 9,374 Three Months Ended September 30, June 30, September 30, 2025 2025 2024 (Restated) Continuing operations CircleDNA $ 2,353 $ 2,210 $ 1,862 IM8 17,214 9,754 — Europa 3,988 5,716 1,666 $ 23,555 $ 17,680 $ 3,528 Note: Revenue by business unit is non-IFRS financial measure and is presented to provide additional insight into the performance of Prenetics' continuing operations. Business unit is not defined under IFRS, may differ from similarly titled measure used by other companies, and should not be considered substitutes for IFRS financial information. Reconciliation of current assets under IFRS and adjusted current assets (Non-IFRS) September 30, December 31, 2025 2024 Current assets under IFRS $ 38,276 $ 75,747 Estimated cash proceeds from the divestment of ACT Genomics 46,305 — Adjusted current assets (Non-IFRS) $ 84,581 $ 75,747 ————————————————————————— [6] Includes equity-settled share-based payment expenses from continuing operations as follows: Nine Months Ended September 30, September 30, 2025 2024 (Restated) Continuing operations Selling and distribution expenses $ 2 $ 4 Research and development expenses 1,167 2,256 Administrative and other operating expenses 2,560 2,168 Total employee equity-settled share-based payment expenses $ 3,729 $ 4,428 Three Months Ended September 30, June 30, September 30, 2025 2025 2024 (Restated) Continuing operations Selling and distribution expenses $ — $ 1 $ 4 Research and development expenses 589 111 690 Administrative and other operating expenses 1,135 968 462 Total employee equity-settled share-based payment expenses $ 1,724 $ 1,080 $ 1,156 [7] ACT Genomics Holdings Company Limited ("ACT Genomics") are classified as discontinued operations in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations ("IFRS 5"). In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.
NANJING, China, Nov. 12, 2025 /PRNewswire/ -- Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025, before the market opens on December 5, 2025. Tuniu's management will hold an earnings conference call at 8:00 am U.S. Eastern Time on December 5, 2025 (9:00 pm Beijing/Hong Kong Time on December 5, 2025). Listeners may access the call by dialing the following numbers: US 1-888-346-8982 Hong Kong 852-301-84992 Mainland China 4001-201203 International 1-412-902-4272 Conference ID: Tuniu 3Q 2025 Earnings Conference Call A telephone replay will be available one hour after the end of the conference call through December 12, 2025. The dial-in details are as follows: US 1-855-669-9658 International 1-412-317-0088 Replay Access Code: 2651018 Additionally, a live and archived webcast of this conference call will be available at http://ir.tuniu.com/. About Tuniu Corporation Tuniu (Nasdaq:TOUR) is a leading online leisure travel company in China that offers integrated travel service with a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network, including a dedicated team of professional customer service representatives, 24/7 call centers, extensive networks of offline retail stores and self-operated local tour operators. For more information, please visit http://ir.tuniu.com.
A12 藝術空間
Earnings
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
